Welcome to our dedicated page for Grifols SEC filings (Ticker: GIKLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
for more than 75 years, grifols has been improving the health and well-being of people. our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. the grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine. grifols has three business divisions: bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. research novel technologies to further improve treatment outcomes and laboratory efficiency. hospital specializes in non-biological pharmaceutical products. tBrandes Investment Partners, L.P. filed an amended Schedule 13G reporting beneficial ownership in Grifols SA. As of 09/30/2025, Brandes reports beneficial ownership of 29,126,291.55 ADRs, representing 19.6% of the class.
The filer reports no sole or shared voting power and shared dispositive power over 29,126,291.55 ADRs. Item 4 also notes holdings of 22,107,370 ordinary shares and 29,126,291.55 ADRs for which dispositive power is shared. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Grifols (GRFS) reported Q3 2025 results with revenue of EUR 1,865 million and quarterly group profit of EUR 127 million, reflecting strong momentum in its Value Creation Plan. Year-to-date revenues reached EUR 5,542 million, up 7.7% at constant currency, while adjusted EBITDA was EUR 1,358 million with a 24.5% margin. Q3 adjusted EBITDA was EUR 482 million, up 8.8% at constant currency, with a 25.8% margin.
Year-to-date net profit was EUR 304 million, up 245%. Free cash flow pre-M&A and pre-dividend was EUR 203 million in Q3, bringing the nine-month total to EUR 188 million, a EUR 257 million improvement versus last year. Leverage improved to 4.2x from 5.1x a year ago, and liquidity rose to EUR 1,475 million.
Growth was led by Biopharma, with a 9.1% constant-currency increase year-to-date and 10.9% in Q3. Immunoglobulin revenues rose 14.4% year-to-date, while subcutaneous IG grew more than 60%. Albumin declined 3.9% year-to-date due to pricing adjustments in China. The Diagnostic business generated EUR 479 million year-to-date, up 1.4%, with FDA approval to begin manufacturing Gel Cards and reagent Red Blood Cells in San Diego. Grifols noted potential full-year FX headwinds of approximately EUR 70 million to adjusted EBITDA if current rates persist.
FAQ
What is the current stock price of Grifols (GIKLY)?
What is the market cap of Grifols (GIKLY)?
